SQZ Cell Engineering Technology Shows Key Advantages for Developing Cell Therapies

WATERTOWN, Mass., Nov. 1, 2018 — SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the peer-reviewed publication of data demonstrating key benefits of the SQZ cell therapy platform in a Proceedings of the National Academy of Sciences (PNAS) paper titled “Cell engineering...
SQZ cell engineering technology shows key advantages for developing cell therapies

WATERTOWN, Mass., Nov. 1, 2018 — SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the peer-reviewed publication of data demonstrating key benefits of the SQZ cell therapy platform in a Proceedings of the National Academy of Sciences (PNAS) paper titled “Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo.”

“At SQZ, we believe in the enormous potential of cell-based therapies. The work put forth in this paper demonstrates that electroporation, the widely used technology behind many gene edited cell therapies, such as modified T cell treatments, can lead to unintended long-term biological consequences that could severely limit the therapeutic potential of engineered cells. Strikingly, the SQZ cell therapy platform does not lead to these negative functional changes,” said Armon Sharei, PhD, chief executive officer and founder of SQZ Biotech and the senior author on the paper. “These data deepen our conviction that the SQZ platform has unique potential to disrupt today’s engineered cell therapies and transform the lives of patients suffering from a range of debilitating diseases.”

In this work, researchers conducted a detailed analysis to determine the downstream functional consequences of electroporation as compared to the

Source: aggregator.leafscience.org